Paper Details

  1. Home
  2. Paper Details

Long-term safety and efficacy of telbivudine in infants born to mothers treated during the second or third trimesters of pregnancy.

Author: DingY, HanG-R, JiangH-X, WangC-M, WangG-J, YueX, ZhaoW, ZhouL

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study evaluated the long-term efficacy and safety of telbivudine, an FDA pregnancy category B drug, in infants born to mothers with chronic hepatitis B infection treated with telbivudine during pregnancy. The results show that telbivudine effectively prevented perinatal HBV transmission and had no significant adverse effects on infant growth and development.
Paper Details　
Original Abstract of the Article :
Telbivudine, an FDA pregnancy category B drug, has been found to reduce hepatitis B virus (HBV) perinatal transmission with no safety concerns in infants aged up to 1 year. This study evaluated the long-term efficacy and safety of telbivudine in 214 infants born to 210 pregnant women with chronic he...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/jvh.12670

データ提供：米国国立医学図書館（NLM）

Telbivudine: A Safe and Effective Treatment for Perinatal Hepatitis B Transmission

This long-term study investigates the safety and efficacy of telbivudine, an FDA pregnancy category B drug, in preventing perinatal hepatitis B virus (HBV) transmission. Researchers followed 214 infants born to mothers who received telbivudine during pregnancy for up to 5 years after birth. They found that none of the infants were infected with HBV, and all maintained effective serum hepatitis B surface antibody (HBsAb) levels. Furthermore, the infants exhibited normal growth and development, with no significant differences in head circumference, weight, height, or congenital abnormality rates.

Telbivudine: A Beacon of Hope for HBV Transmission Prevention

This study provides reassuring evidence that telbivudine is a safe and effective treatment for preventing perinatal HBV transmission. The long-term follow-up data demonstrates its ability to protect infants from HBV infection without compromising their growth and development. These findings are particularly important for mothers with chronic hepatitis B infection, offering a chance to safeguard their children from this potentially serious viral disease.

Navigating the Desert of Perinatal Transmission

Imagine a mother with HBV traversing a vast desert, hoping to protect her child from the dangers of infection. Telbivudine, like a reliable guide, helps navigate this challenging journey, providing a safe passage for the infant through the desert of perinatal transmission.

Dr. Camel's Conclusion

Telbivudine proves to be a safe and effective treatment for preventing perinatal HBV transmission, offering a beacon of hope for mothers with chronic hepatitis B infection. The long-term follow-up data reinforces its safety and effectiveness, ensuring that infants can thrive without the risk of HBV infection. This study serves as a valuable resource for healthcare professionals seeking to safeguard the health of mothers and their children.
Date :
  1. Date Completed 2018-02-14
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

28039902

DOI: Digital Object Identifier

10.1111/jvh.12670

Related Literature

Article Analysis
・Side Effects of telbivudine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.